Porcine xenotransplantation antigens (alpha-Gal)

The recognition of porcine kidney and thymic tissue antigens by the human immune system is the primary immunological barrier to successful xenotransplantation. This process is initiated by the binding of pre-existing human natural antibodies to porcine carbohydrate antigens, most notably Galactose-alpha-1,3-galactose (alpha-Gal), which is expressed on the surface of pig vascular endothelial cells but absent in humans (Cooper et al., 2015). This binding triggers the classical complement pathway, leading to hyperacute rejection (HAR) characterized by rapid graft thrombosis and loss within minutes to hours (Montgomery et al., 2022). Beyond alpha-Gal, other non-human antigens such as N-glycolylneuraminic acid (Neu5Gc) and Swine Leukocyte Antigens (SLA) contribute to acute vascular and cellular rejection (Lu et al., 2022). Current therapeutic approaches involve the use of genetically engineered pigs, such as the GalSafe pig, which lacks the alpha-1,3-galactosyltransferase gene, and the administration of complement inhibitors like eculizumab or costimulation blockers like belatacept to the recipient (Griffith et al., 2022). Managing this recognition is critical for the clinical viability of xenotransplantation as a solution for the global organ shortage (Mohiuddin et al., 2016).

Other names

Galactose-alpha-1,3-galactosealpha-GalXenogeneic antigensPorcine kidney antigensPorcine thymic antigensN-glycolylneuraminic acidNeu5GcSwine Leukocyte AntigenSLASDa antigen

Prevention of rejection through complement inhibition, T-cell costimulation blockade, B-cell depletion, and genetic deletion of donor antigens (e.g., alpha-1,3-galactosyltransferase gene knockout).